汇宇制药-W (688553.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

232.9x

Market Cap

CNY 7.54B

MomentumView details →

1D Return

+1.01%

YTD Return

—

RSI (14)

51.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

232.9x

Market Cap

CNY 7.54B

RSI (14)

51.2

MomentumView details →

1D Return

+1.01%

YTD Return

—

ProfitabilityView details →

Gross Margin

78.56%

Net Margin

2.19%

EBITDA Margin

2.39%

ROE (TTM)

0.60%

ROA (TTM)

0.44%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

−5.73%

EPS YoY

−91.15%

FCF YoY

−77.79%

Revenue CAGR 3Y

−12.57%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.06

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.18x

Current Ratio

2.61x

Quick Ratio

2.39x

Div Yield

1.67%

Div Rate

CNY 0.20

Div Growth 1Y

−36.10%

Financials snapshotView financials →

Revenue (TTM)

1.03B

Net Income (TTM)

22.53M

Op. CF (TTM)

108.12M

Latest newsMore news →

Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received approval from China's National Medical Products Administration to conduct clinical trials for its investigational drug HY07121 (subcutaneous injection) for treating advanced solid tumors.17d ago

Huiyu Pharmaceutical's subsidiary Seacross (Europe) Pharma Ltd. received marketing approvals from German, Dutch, and Spanish regulators for its products parecoxib sodium for injection and zoledronic acid injection.26d ago

Similar companies

鲁抗医药600789.SH 上海谊众688091.SH Sihuan Pharmaceutical Holdings Group Ltd.00460.HK 阳光诺和688621.SH 太极集团600129.SH CanSino Biologics Inc.06185.HK Find similar companies →

Latest newsMore news →

Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received approval from China's National Medical Products Administration to conduct clinical trials for its investigational drug HY07121 (subcutaneous injection) for treating advanced solid tumors.17d ago Huiyu Pharmaceutical's subsidiary Seacross (Europe) Pharma Ltd. received marketing approvals from German, Dutch, and Spanish regulators for its products parecoxib sodium for injection and zoledronic acid injection.26d ago